Video Highlights
1:13 Sahil Khanna, MBBA, MS
2:42 Glenn Tillotson, PhD, FIDSA, FCCP
3:35 Payal Patel, MD, MPH
4:12 Anurag Malani, MD
|Videos|August 1, 2021
Where Are We With Clostridioides Difficile?
Author(s)John Parkinson
What are the efforts being made with antibiotic stewardship and treatments, and what areas in clinical care do medical professionals want to see improvements.
Advertisement
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: Looking at C diff as a whole, would you say the medical community is doing a better job overall of treatment and what challenges remain?
We interviewed Sahil Khanna, MBBS, MS, who is professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic; Glenn Tillotson, PhD, FIDSA, FCCP, GST Micro LLC; Payal K. Patel, MD, MPH, Division of Infectious Diseases assistant professor, University of Michigan Health System and medical director of Antimicrobial Stewardship, VA Ann Arbor; and Anurag Malani, MD, infectious diseases specialist, St. Joseph Hospital, and a fellow of Infectious Diseases Society of America (IDSA).
Check out our video to hear their insights.
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
2
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
3
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
4
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
5